Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2022-05-08 Major Shareholding Noti…
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
昆药集团详式权益变动报告书
Major Shareholding Notification Classification · 95% confidence The document is titled "详式权益变动报告书" which translates to "Detailed Equity Change Report". It is issued by a shareholder (华润三九医药股份有限公司) regarding a significant change in shareholding in 昆药集团股份有限公司. The document references relevant Chinese securities laws and regulations specifically related to equity changes and acquisitions, such as the "上市公司收购管理办法" (Measures for the Administration of Takeovers of Listed Companies) and disclosure standards for equity changes and takeover reports. The content includes detailed information about the shareholder, the nature of the equity change (increase by agreement transfer), the purpose of the change, the share transfer agreement, funding sources, future plans, impact analysis, and financial data of the shareholder. This is a comprehensive report on a major shareholding change, not a simple announcement or a proxy statement. It is not an annual report, earnings release, or management report. It is specifically a detailed equity change report, which corresponds to the category "Major Shareholding Notification" (Code: MRQ). The document length (15,000 characters) and detailed content confirm it is the report itself, not just an announcement or certification. Therefore, the correct classification is MRQ with high confidence.
2022-05-08 Chinese
昆药集团关于控股股东、实际控制人拟发生变更暨公司股票复牌的提示性公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from Kunming Pharmaceutical Group Co., Ltd. regarding a proposed change in the controlling shareholder and actual controller due to a share transfer agreement. It details the transaction, the parties involved, the shareholding changes, and the conditions that must be met before completion. It also announces the resumption of trading of the company's stock after a suspension related to this matter. The document is relatively short (2175 characters) and serves as a notification or announcement about the shareholding change and stock resumption, rather than a detailed financial report or a full regulatory filing. It does not contain financial statements or detailed management discussion, nor is it a certification or proxy material. It fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement about a significant corporate event that does not fit other more specific categories like M&A filings or major shareholding notifications (which usually focus on threshold crossing rather than control changes). Therefore, the classification is Regulatory Filings (RNS) with high confidence.
2022-05-08 Chinese
昆药集团关于控股股东筹划重大事项的停牌公告
Regulatory Filings Classification · 95% confidence The document is a notice about the suspension of trading (停牌公告) due to the controlling shareholder planning a major matter involving potential change in control. It references regulatory rules for suspension and resumption of trading and states the stock will be suspended for up to two trading days. The document is short (816 characters) and is an announcement of a trading halt, not a financial report or detailed filing. This fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement about trading suspension and does not contain financial data or detailed report content.
2022-05-05 Chinese
昆药集团2021年年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a resolution announcement from the 2021 Annual General Meeting (AGM) of Kunming Pharmaceutical Group Co., Ltd. It details the date and location of the meeting, attendance, voting results on various proposals including the 2021 annual report, financial statements, profit distribution, and other corporate governance matters. The document is a formal announcement of the voting results and resolutions passed at the AGM, not the full annual report or financial statements themselves. The document length is 4379 characters, which is relatively short and consistent with a voting results announcement rather than a full report. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2022-04-28 Chinese
昆药集团2021年年度股东大会的法律意见
AGM Information Classification · 100% confidence The document is a legal opinion from a law firm regarding the 2021 Annual General Meeting (AGM) of Kunming Pharmaceutical Group Co., Ltd. It details the convening, attendance, voting procedures, and results of the AGM. The content focuses on the AGM process and legal compliance rather than the full annual report or financial statements. The document length is short (1655 characters) and it is clearly related to the AGM event itself, not a report publication announcement or other filing. Therefore, the document fits the category of AGM Information (AGM-R).
2022-04-28 Chinese
昆药集团2022年第一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '2022 年第一季度报告' which translates to '2022 First Quarter Report'. It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and management commentary for the first quarter of 2022. The report explicitly states it is unaudited and covers the period January to March 2022. The length of the document (13,933 characters) and the presence of comprehensive financial statements and analysis confirm it is a full quarterly financial report rather than a brief announcement or summary. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q1 2022
2022-04-15 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.